{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:11:06Z","timestamp":1791897066529,"version":"4.3.4"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor thrombus (TT), defined as intravascular extension of malignant tissue, is a distinct manifestation of cancer-associated thrombosis driven by malignant vascular invasion rather than fibrin-rich clot. Despite limited evidence, anticoagulant therapy is frequently prescribed empirically. This systematic review synthesized available data on the effectiveness and safety of anticoagulation in adults with solid tumor\u2013associated TT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A PRISMA (2020) compliant systematic review (PROSPERO-registered) was conducted using PubMed\/MEDLINE, Embase, and CENTRAL through September 2025. Eligible studies included adults with solid tumor\u2013associated TT who received anticoagulation and reported thrombus response, thromboembolic recurrence, survival, or bleeding outcomes. Results were synthesized narratively in accordance with SWiM guidance. Risk of bias was assessed using the Newcastle\u2013Ottawa Scale and the Joanna Briggs Institute tools, and the certainty of evidence was assessed using the GRADE approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight studies met the inclusion criteria, comprising three retrospective cohort studies and five case reports. Anticoagulants evaluated included low-molecular-weight heparin, vitamin K antagonists, direct oral anticoagulants, unfractionated heparin, and parenteral direct thrombin inhibitors. Across all studies, anticoagulation alone was not associated with radiographic regression of TT. Apparent thrombus resolution occurred exclusively following tumor-directed or mechanical interventions, such as surgical thrombectomy or percutaneous aspiration, and could not be attributed to anticoagulation alone. Evidence for a reduction in thromboembolic recurrence was limited, heterogeneous, and inconsistently adjudicated as bland thrombosis versus malignant embolic disease. No survival benefit attributable to anticoagulation was demonstrated. In contrast, anticoagulant therapy was associated with a clinically meaningful risk of major bleeding, particularly among patients with renal cell carcinoma\u2013associated TT. Overall certainty of evidence ranged from very low to moderate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence does not demonstrate a consistent benefit of routine anticoagulation for isolated TT. Anticoagulation may be appropriate when conventional indications are present (e.g., pulmonary embolism, proximal deep-vein thrombosis, atrial fibrillation, catheter-associated thrombosis). Tumor-directed therapy remains the primary determinant of outcomes. Prospective studies are needed to define optimal management strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251111117<\/jats:ext-link>\n                      , identifier CRD420251111117.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1773327","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:27:25Z","timestamp":1771824445000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Anticoagulant outcomes in managing tumor thrombus: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Lama","family":"Alfehaid","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaher","family":"Alatmi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]},{"name":"Pharmaceutical Care Department, King Saud University Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishier","family":"Alfadhel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shooa","family":"bin Nafisah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"AlSheef","sequence":"additional","affiliation":[{"name":"King Fahad Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Alsuhebany","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad116","article-title":"Treatment of cancer-associated thrombosis: recent advances, unmet needs, and future direction","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvn.2022.09.004","article-title":"Venous thromboembolism (VTE) risk assessment in cancer patients receiving chemotherapy in a tertiary care center","volume":"40","author":"Varghese","year":"2022","journal-title":"J Vasc Nurs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024828","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism","volume":"2","author":"Lim","year":"2018","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/diseases9020034","article-title":"Cancer-associated thrombosis: a new light on an old story","volume":"9","author":"Shah","year":"2021","journal-title":"Diseases"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21037\/cdt.2017.09.16","article-title":"Tumor thrombus: incidence, imaging, prognosis and treatment","volume":"7","author":"Quencer","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.10.002","article-title":"Management and outcomes in patients with tumor thrombus: a retrospective cohort study","volume":"23","author":"Hui","year":"2024","journal-title":"J Thromb Haemost"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2023.09.004","article-title":"Breaking down tumor thrombus: current strategies for medical management","volume":"230","author":"Tathireddy","year":"2023","journal-title":"Thromb Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.07.011","article-title":"Prevalence, treatment, and prognosis of tumor thrombi in renal cell carcinoma","volume":"4","author":"Kaptein","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40644-024-00657-z","article-title":"Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion","volume":"24","author":"Balcar","year":"2024","journal-title":"Cancer Imaging"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2017.02.036","article-title":"Successful team-based management of renal cell carcinoma with caval extension of tumor thrombus above the diaphragm","volume":"31","author":"Spelde","year":"2017","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2023.101896","article-title":"A case of pulmonary tumor embolism syndrome with thrombus in transit","volume":"45","author":"F\u00fchrer","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(23)04368-1","article-title":"Intracardiac tumor thrombus in Malignant melanoma: a ball valve obstruction","volume":"81","author":"Barron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13256-025-05157-7","article-title":"Primary Ewing sarcoma of renal origin with tumor thrombus into inferior vena cava: a case report","volume":"19","author":"Khajeh-Mehrizi","year":"2025","journal-title":"J Med Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4065\/77.6.595","article-title":"Fatal tumor thrombosis due to an inferior vena cava leiomyosarcoma in a patient with antiphospholipid antibody syndrome","volume":"77","author":"Espiritu","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood-2019-124476","article-title":"Natural history of tumor thrombus: a single-centre retrospective study","volume":"134","author":"Marcoux","year":"2019","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1773327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:27:26Z","timestamp":1771824446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1773327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1773327"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1773327","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1773327"}}